急性髓系白血病表观遗传治疗:路在何方?
急性髓系白血病(AML)以表观遗传失调为特征,表现为髓系分化阻滞和恶性自我更新增强。本文综述了全球监管机构已批准及处于早期临床试验阶段的表观遗传治疗,讨论了临床前乐观与早期临床试验结果之间的差距及其概念和分子因素,并探讨了联合治疗策略与新型表观遗传药物的开发方向。
要点
- AML的表观遗传失调由转录因子和染色质调控因子的反复易位和/或突变引发。
- 临床前研究支持表观遗传治疗,但早期临床试验结果更为审慎。
- 需要理解临床前与临床结果差异的机制,并探索联合治疗与新型药物。
核心结论
- 表观遗传治疗在AML中具有理论前景,但早期临床试验结果较临床前研究更为审慎,需进一步研究以改善患者结局。
研究设计与样本
- 本文为综述,概述了全球监管机构已批准及处于早期临床试验阶段的表观遗传治疗,并讨论相关概念与分子因素。
主要发现
- AML的表观遗传失调由反复易位和/或转录因子及染色质调控因子突变引发,导致髓系分化阻滞和恶性自我更新增强。
- 临床前研究曾引发对表观遗传治疗改变AML自然病程的广泛乐观,但早期临床试验结果提供了更审慎的信息。
临床怎么用
- 文章讨论了将当前一代表观遗传治疗与其他类别药物联合的策略,以及新型表观遗传治疗的开发方向。
局限性
- 文章讨论了可能解释临床前与临床结果差异的概念和分子因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A hallmark of acute myeloid leukemia (AML) is epigenetic dysregulation, which is initiated by recurrent translocations and/or mutations in transcription factors and chromatin regulators. This manifests as a block in myeloid differentiation and an increase in malignant self-renewal. These common features of AML have led to widespread optimism that epigenetic therapies would dramatically change the natural history of this disease. Although preclinical studies with these drugs fueled this optimism, results from early clinical trials have offered a more sobering message. Here, we provide an overview of epigenetic therapies that are currently approved by therapeutic regulatory authorities across the world and those undergoing early-phase clinical trials. We also discuss the conceptual and molecular factors that may explain some of the disparity between the bench and bedside, as well as emerging avenues for combining the current generation of epigenetic therapies with other classes of agents and the development of novel epigenetic therapies. With further research and development of this exciting class of drugs, we may finally be able to dramatically improve outcomes for patients afflicted with this aggressive and often incurable malignancy.
引用
- Fennell KA, Bell CC, Dawson MA, et al. Epigenetic therapies in acute myeloid leukemia: where to from here? Blood. 2019. PMID: 31697822. doi:10.1182/blood.2019003262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。